Thyrocare Technologies's total inventories for the quarter that ended in Mar. 2026 was ₹485 Mil. Thyrocare Technologies's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was ₹242 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Thyrocare Technologies's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was ₹9.36.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Thyrocare Technologies's Days Inventory for the
three
months ended in Mar. 2026 was 39.01.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Thyrocare Technologies's Inventory Turnover for the quarter that ended in Mar. 2026 was 2.34.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Thyrocare Technologies's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.11.
Thyrocare Technologies (NSE:THYROCARE) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Thyrocare Technologies's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Thyrocare Technologies's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Thyrocare Technologies Total Inventories Related Terms
Thyrocare Technologies Total Inventories Historical Data
* Premium members only.
The historical data trend for Thyrocare Technologies's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thyrocare Technologies Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Thyrocare Technologies (NSE:THYROCARE) has a Total Inventories of ₹485 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Thyrocare Technologies and its competitors.
Is Thyrocare Technologies' Total Inventories too high?
Thyrocare Technologies' current Total Inventories is ₹485 Mil. Overall, Thyrocare Technologies has a GF Score™ of 87/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Thyrocare Technologies' Total Inventories compare to TMO and DHR?
Thyrocare Technologies' Total Inventories of ₹485 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Medical Diagnostics & Research company?
A good Total Inventories depends on the Medical Diagnostics & Research industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Thyrocare Technologies and its competitors. Thyrocare Technologies's current Total Inventories is ₹485 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thyrocare Technologies stock overvalued right now?
Based on GuruFocus' analysis, Thyrocare Technologies (NSE:THYROCARE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹392.73, compared to a current price of ₹549.30 — trading 39.9% above its estimated fair value. The current Total Inventories is ₹485 Mil. Thyrocare Technologies' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Thyrocare Technologies (NSE:THYROCARE), the current Total Inventories is ₹485 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Thyrocare Technologies (NSE:THYROCARE) Overvalued in 2026?
Based on GuruFocus' analysis, Thyrocare Technologies stock appears to be overvalued.
The current stock price of ₹549.30 is trading 39.9% above its estimated GF Value™ of ₹392.73.
GuruFocus considers Thyrocare Technologies to be Significantly Overvalued.
Key valuation signals for NSE:THYROCARE:
Total Inventories: ₹485 Mil
GF Value™: ₹392.73 vs. price of ₹549.30 (39.9% above fair value)
No single metric tells the full story. See the NSE:THYROCARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Thyrocare Technologies Ltd is a diagnostics & research company. The company has three business segments: Diagnostic Testing Services, Imaging Services, and Others: Sale of testing equipment and consumables. The Diagnostic Testing Services segment provides Diagnostic and testing services, selling of consumables used for the collection and promotion of the pathology segment. The company majorly earns the majority of its revenue from the Diagnostic Testing Services segment. The Imaging Services segment operates Diagnostic and imaging services, selling of radio-pharmaceuticals, and selling of consumables for reporting. The Other business segment is engaged in the selling of glucometers and glucostrips under the brand name Sugarscan. The company earns the vast majority of its revenue in India.
87GF Score
Get the complete analysis for NSE:THYROCARE
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:THYROCARE has been successfully added to your 
